Allied Market Research
image  Direct : +1 (617) 674-4143 | Toll Free : +1 (855) 711-1555

Report Image
Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forecast, 2013 - 2020
Published: Dec-2013    |    Formats: PDF & Excel   |   Author(s):Debbie Shields and Roshan Deshmukh   |   Code: DI 1387
  • Report
    Overview
  • Table of
    Contents
  • Research
    Methodology
  • Analyst's
    Review
  • Download
    Sample

Pages
151

Biomarkers are novel diagnostic tools that provide intelligence to physician about disease progression and treatment effects. Advancement in understanding of human genome promotes its application in diagnosis of disease on molecular basis. Biomarker technology is evidencing increased application in disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments. The global market for diagnostic biomarker is expected to reach about $30.6 billion in 2020, growing at CAGR of 16% from 2013 to 2020. Pharmaceutical companies, which are interested in introducing novel diagnostic solution are increasing partnership and collaboration with private laboratories, and educational institutes. The companies are also increasing their investments in research and development.
Disease diagnostic application remains the key area of application that is expected to reach 6.1 $billion in 2020. However, application of diagnostic biomarkers in forensics and molecular diagnostics is catching up quite significantly. Molecular diagnostics is expected to grow at a CAGR of 17.6% from 2013 to 2020.
The key players in this market that are profiled in the report include: Roche Diagnostic Limited (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Aushon BioSystem Inc. (M.A.), Epistem Ltd (U.K.), G.E. Healthcare Inc.(U.K).

Biomarker market growing steadfastly.

KEY BENEFITS

  • Assessment and ranking the factors that favor the market growth and those factors which act as a hindrance for the growth of the market
  • The market sizing and estimation period is from 2013 to 2020. Two historic years include 2011 and 2012
  • The report identifies and analyses top investment pockets and top winning strategies for diagnostic biomarker market
  • The report analyses the various strategies adopted by some of the key companies in the market
  • The report tracks and analyses key innovations and patents for biomarkers in the last five years

 

KEY MARKET SEGMENTS
DIAGNOSTIC BIOMARKER MARKET IS SEGMENTED AS FOLLOWS:
GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY TYPES

  • Biomarker of Exposure
  • Biomarkers of Diseases

GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY APPLICATIONS

  • Risk Assessment
  • Development of Molecular Diagnostic
  • Disease Diagnosis
  • Drug Discovery and Development
  • Drug Formulation
  • Forensic Application
  • Others (DNA Fingerprinting and Others)

GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY SERVICES

  • Sample Preparation
  • Assay Development
  • Biomarker Validation and Testing
  • Other Services

GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • Row (Rest of World)

KEY AUDIENCES

  • Pharmaceutical companies
  • Government & Private research institutes
  • Academic institutes
  • Medical device manufacturing companies

 

 


Tables
53

CHAPTER 1 INTRODUCTION

1.1 Scope and Coverage
1.2 Report Description

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Biomarker Diagnosis Vs. Conventional Diagnosis
2.2 Why Diagnostic Biomarkers are Used in Diagnosis and Drug Development?

CHAPTER 3 MARKET OVERVIEW

3.1 Key Application of Diagnostic Biomarkers in Top Technologies

3.1.1 Omics Technology

3.1.1.1 Applications of Omics Technology

3.1.1.1.1 Lung Disease Identification
3.1.1.1.2 Quantifying Abnormalities
3.1.1.1.3 Genetic Trait Diagnosis
3.1.1.1.4 Analyzing Drug Efficiency
3.1.1.1.5 Functional Food Development
3.1.1.1.6 Pharmacogenomics
3.1.1.1.7 Drivers
3.1.1.1.8 Restraints

3.1.1.1.8.1 Lengthy Process
3.1.1.1.8.2 Ethical Problems
3.1.1.1.8.3 Sample Collection
3.1.1.1.8.4 Gene Expression
3.1.1.1.8.5 Inefficiency in Pre-Disease Identification

3.1.2 Imaging Technology

3.1.2.1 Application of Diagnostic Imaging Technology
3.1.2.2 Drivers

3.1.2.2.1 Faster Test Result
3.1.2.2.2 Improved Nursing Services
3.1.2.2.3 Noninvasive Technique

3.1.2.3 Restraints

3.1.2.3.1 Radiation Effect
3.1.2.3.2 Complex Process
3.1.2.3.3 Genetic Variation

3.1.2.4 Trends

3.1.3 Bioinformatics

3.1.3.1 Applications of Bioinformatics
3.1.3.2 Drivers

3.1.3.2.1 Open Source of Information
3.1.3.2.2 Relevant Information
3.1.3.2.3 Forecasting of Information

3.1.3.3 Restraints

3.1.3.3.1 Difficulty in Practical Application
3.1.3.3.2 Over-Fitting
3.1.3.3.3 Complex Operation Process
3.1.3.3.4 Security Issue
3.1.3.3.5 Costly Management
3.1.3.3.6 Virtual Storage

3.1.4 Personalized Medicines

3.1.4.1 Drivers

3.1.4.1.1 Unique Solution
3.1.4.1.2 Minimal Invasive
3.1.4.1.3 Reduction in Failure
3.1.4.1.4 Effective Prescription

3.1.4.2 Restraints

3.1.4.2.1 Need Specialized Setup for Treatment
3.1.4.2.2 Liability Issue
3.1.4.2.3 Ethical Question

3.1.5 Others (Nutritional Technology)

3.2 Importance of Non-Invasive Diagnostics
3.3 Key Advantages of Dm
3.4 Regulatory Scenario
3.5 Reimbursement Issues
3.6 Key Patents and Analysis
3.7 Top Ten Factors Impacting DBM Market

3.7.1 Non-Invasive Technique
3.7.2 Drug Discovery and Development
3.7.3 Cost Effective Tool for Diagnosis
3.7.4 Multi-Marker Application
3.7.5 Accuracy and Reliability
3.7.6 Ethical Issues
3.7.7 Gene Level Diagnosis
3.7.8 Complex Processes
3.7.9 Government Regulations
3.7.10 Reimbursement Issues

3.8 Top Investment Pockets
3.9 Market Intelligence

3.9.1 Top Three Winning Strategies

3.9.1.1 Product Launch
3.9.1.2 Collaboration and Agreement
3.9.1.3 Merger and Acquisition

3.10 Market Dynamics

3.10.1 Drivers

3.10.1.1 Cost Effective
3.10.1.2 Non-Invasive
3.10.1.3 Accuracy in Result
3.10.1.4 Assistant in Clinical Trials
3.10.1.5 Multi-Marker Application
3.10.1.6 Gene Level Diagnosis

3.10.2 Restrains

3.10.2.1 Government Regulation
3.10.2.2 Ethical Problems
3.10.2.3 Conformation in Result
3.10.2.4 Complex Process

3.10.3 Opportunity

3.10.3.1 Local Market
3.10.3.2 Personalized Medicine
3.10.3.3 Tissue Specific Treatment

CHAPTER 4 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY TYPES, 2013-2020, $MILLION

4.1 Biomarker of Exposure
4.2 Biomarkers of Disease

CHAPTER 5 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY APPLICATIONS, 2013-2020, $MILLION

5.1 Risk Assessment

5.1.1 Applications

5.1.1.1 Oncology Treatment
5.1.1.2 Cardiovascular Treatment

5.1.2 Drivers

5.1.2.1 Forecasting of Abnormal Conditions
5.1.2.2 Cost Effective

5.1.3 Restraints

5.1.3.1 Government Regulations
5.1.3.2 Ethical Issues

5.2 Development of Molecular Diagnostic

5.2.1 Application

5.2.1.1 Prenatal Diagnostics
5.2.1.2 Human Clinical Molecular Diagnostic Testing
5.2.1.3 Veterinary Molecular Diagnostic Testing
5.2.1.4 Identity Testing
5.2.1.5 Histocompatibility Testing

5.2.2 Drivers

5.2.2.1 Uniformity in Test Result
5.2.2.2 Cost Effective
5.2.2.3 Fast Result
5.2.2.4 More Profitable
5.2.2.5 Automation

5.2.3 Restraints

5.2.3.1 Not Applicable for Twins Genomes
5.2.3.2 Government Regulations
5.2.3.3 Ethical Issues

5.3 Disease Diagnosis

5.3.1 Oncology

5.3.1.1 Drivers
5.3.1.2 Restraints

5.3.1.2.1 Complex Process
5.3.1.2.3 Used for Early Diagnosis Only

5.3.2 Cardiology

5.3.2.1 Application
5.3.2.2 Drivers

5.3.2.2.1 Cost Effective
5.3.2.2.2 Tissue Specific
5.3.2.2.3 Accurate Result

5.3.2.3 Restraints

5.3.2.3.1 Loss of Specificity
5.3.2.3.2 Low Specificity
5.3.2.3.3 Low Sensitivity

5.3.3 Neurology

5.3.3.1 Application
5.3.3.2 Drivers

5.3.3.2.1 Relevant Information
5.3.3.2.2 Efficient Diagnosis
5.3.3.2.3 Assistant in Clinical Trials

5.3.3.3 Restraints

5.3.3.3.1 Complex Process
5.3.3.3.2 Chromosomal Variation
5.3.3.3.3 Hurdles in Tracking

5.3.3.4 Alzheimer’s
5.3.3.5 Multiple Sclerosis
5.3.3.6 Parkinson's Disease
5.3.3.7 Others (Renal Diseases, Urinal Disease)

5.4 Drug Discovery and Development

5.4.1 Application
5.4.2 Drivers

5.4.2.1 Increased Efficiency
5.4.2.2 High Quality Support
5.4.2.3 Cost Effective
5.4.2.4 Collaboration for Novel Development

5.4.3 Restraints

5.4.3.1 Drug Metabolism
5.4.3.2 Stability of Biomarkers
5.4.3.3 Complex Process

5.5 Drug Formulation

5.5.1 Application
5.5.2 Drivers
5.5.3 Restraint

5.6 Forensic Application

5.7 Others (Dna Fingerprinting and Others)

5.7.1 Blood Alcohol Concentration Biomarker
5.7.2 Dna Fingerprinting

CHAPTER 6 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY SERVICES, 2013-2020, $MILLION

6.1 Sample Preparation

6.1.1 Application

6.1.1.1 Biological Mass Spectrometry

6.1.2 Drivers

6.1.2.1 Cost Effective
6.1.2.2 Sample Rigidity
6.1.2.3 Efficient Forensic Studies

6.1.3 Restraints

6.1.3.1 Complex Structure
6.1.3.2 Lack of Effectiveness
6.1.3.3 Extensive Fractionation
6.1.3.4 Loss of Biological Compounds

6.2 Assay Development

6.2.1 Application

6.2.1.1 Clinical Trials
6.2.1.2 Drug Development and Validation
6.2.1.3 Others

6.2.2 Drivers

6.2.2.1 Accuracy
6.2.2.2 Cost Effective
6.2.2.3 imely Result

6.2.3 Restraints

6.2.3.1 Complexity in Technique
6.2.3.2 Tissue Specific

6.3 Biomarker Validation and Testing 

6.3.1 Drivers

6.3.1.1 Reduce Failure Rate

6.3.2 Restraints

6.3.2.1 Clinical Errors
6.3.2.2 Time Consuming

6.4 Other Services

CHAPTER 7 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY GEOGRAPHY, 2013-2020, $MILLION

7.1 North America
7.2 Europe
7.3 Asia-Pacific
7.4 Row (Rest of World)

CHAPTER 8 COMPETITIVE LANDSCAPE

8.1 Product Launch

8.1.1 Recent Development

8.2 Collaboration and Partnership

8.2.1 Recent Development

8.3 Clearance and Approval

8.3.1 Recent Development

8.4 Mergers and Acquisition

8.4.1 Recent Development

CHAPTER 9 COMPANY PROFILES

9.1 Abbott Laboratories, Inc.

9.1.1 Company Overview
9.1.2 Company Snapshot
9.1.3 Business Performance
9.1.4 Strategic Moves and Developments

9.1.4.1 Principal Strategies
9.1.4.2 Secondary Strategies

9.1.5 Swot Analysis & Strategic Conclusions

9.2 Agilent Technologies Inc.

9.2.1 Company Overview
9.2.2 Company Snapshot
9.2.3 Business Performance
9.2.4 Strategic Moves and Developments

9.2.4.1 Primary Strategies
9.2.4.2 Secondary Strategies

9.2.5 Swot Analysis & Strate

9.3 Aushon Biosystem

9.3.1 Company Profile
9.3.2 Company Snapshot
9.3.3 Strategic Moves and Developments

9.3.3.1 Primary Strategies
9.3.3.2 Secondary Strategies

9.3.4 Swot Analysis & Strategic Conclusions

9.4 Bio-Rad Laboratories

9.4.1 Company Profile
9.4.2 Company Snapshot
9.4.3 Business Performance
9.4.4 Strategic Moves and Developments

9.4.4.1 Primary Strategies
9.4.4.2 Secondary Strategies

9.4.5 Swot Analysis & Strategic Conclusions

9.5 Eisai Co. Ltd.

9.5.1 Company Profile
9.5.2 Company Snapshot
9.5.3 Business Performance
9.5.4 Strategic Moves and Developments

9.5.4.1 Primary Strategies
9.5.4.2 Secondary Strategies

9.5.5 Swot Analysis & Strategic Conclusions

9.6 Epistem Ltd.

9.6.1 Company Profile
9.6.2 Company Snapshot
9.6.3 Business Performance
9.6.4 Strategic Moves and Developments

9.6.4.1 Primary Strategies
9.6.4.2 Secondary Strategies

9.6.5 Swot Analysis & Strategic Conclusions

9.7 Ge Healthcare

9.7.1 Company Profile
9.7.2 Company Snapshot
9.7.3 Business Performance
9.7.4 Strategic Moves and Developments

9.7.4.1 Principle Strategies
9.7.4.2 Secondary Strategies

9.7.5 Swot Analysis & Strategic Conclusions

9.8 Roche Diagnostics Limited

9.8.1 Company Profile
9.8.2 Company Snapshot
9.8.3 Business Performance
9.8.4 Strategic Moves and Developments

9.8.4.1 Principal Strategies
9.8.4.2 Secondary Strategies

9.8.5 Swot Analysis & Strategic Conclusions

9.9 Siemens AG

9.9.1 Company Profile
9.9.2 Company Snapshot
9.9.3 Business Performance
9.9.4 Strategic Moves and Developments

9.9.4.1 Primary Strategies
9.9.4.2 Secondary Strategies

9.9.5 Swot Analysis & Strategic Conclusions

 9.10 Thermo Fisher Scientific Inc.

9.10.1 Company Profile
9.10.2 Company Snapshot
9.10.3 Business Performance
9.10.4 Strategic Moves and Developments

9.10.4.1 Primary Strategies
9.10.4.2 Secondary Strategies

9.10.5 Swot Analysis & Strategic Conclusions

 

LIST OF TABLES:

TABLE 1 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY REVENUE 2011-2020 ($MILLION)
TABLE 2 GLOBAL DIAGNOSTIC BIOMARKER MARKET BY APPLICATION 2011-2020 ($MILLION)
TABLE 3 GLOBAL DIAGNOSTIC BIOMARKER MARKET FOR TECHNOLOGY 2011-2020 ($MILLION)
TABLE 4 DIAGNOSTIC BIOMARKER APPLICATION MARKET 2011-2020 ($MILLION)
TABLE 5 DIAGNOSTIC BIOMARKER APPLICATION MARKET 2011-2020 ($MILLION)
TABLE 6 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF IMAGING TECHNOLOGY 2011-2020 ($MILLION)
TABLE 7 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF BIOINFORMATICS 2011-2020 ($MILLION)
TABLE 8 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF PERSONALIZED MEDICINE 2011-2020 ($MILLION)
TABLE 9 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER DISEASES 2011-2020 ($MILLION)
TABLE 10 BIOMARKERS MARKET BY TYPES IN 2011-2020 ($MILLION)
TABLE 11 GLOBAL MARKET FOR BIOMARKERS OF EXPOSURE IN 2011-2020 ($MILLION)
TABLE 12 GLOBAL MARKET FOR BIOMARKERS OF EXPOSURE IN 2011-2020 ($MILLION)
TABLE 13 DIAGNOSTIC BIOMARKER APPLICATION MARKET IN 2011-2020 ($MILLION)
TABLE 14 GLOBAL DIAGNOSTIC BIOMARKER MARKET APPLICATION MARKET IN 2011-2020 ($MILLION)
TABLE 15 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF RISK ASSESSMENT IN 2011-2020 ($MILLION)
TABLE 16 GLOBAL DIAGNOSTIC BIOMARKER MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC IN 2011-2020 ($MILLION)
TABLE 17 DIAGNOSTIC BIOMARKER MARKET OF DISEASE DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 18 GLOBAL DIAGNOSTIC BIOMARKER MARKET FOR DEVELOPMENT OF MOLECULAR DIAGNOSTIC IN 2011-2020 ($MILLION)
TABLE 19 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF CARDIOLOGY DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 20 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF CARDIOLOGY DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 21 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF NEUROLOGY DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 22 DIAGNOSTIC BIOMARKER MARKET FOR NEUROLOGY DISEASE DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 23 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER DISEASE DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 24 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER DISEASE DIAGNOSIS IN 2011-2020 ($MILLION)
TABLE 25 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF DRUG FORMULATION IN 2011-2020 ($MILLION)
TABLE 26 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF FORENSIC APPLICATION IN 2011-2020 ($MILLION)
TABLE 27 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER DISEASES IN 2011-202 ($MILLION)
TABLE 28 DIAGNOSTIC BIOMARKER MARKET OF SERVICES IN 2011-202($MILLION)
TABLE 29 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF SERVICES IN 2011-2020 ($MILLION)
TABLE 30 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF SAMPLE PREPARATION IN 2011-2020 ($MILLION)
TABLE 31 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF ASSAY DEVELOPMENT IN 2011-2020 ($MILLION)
TABLE 32 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF BIOMARKER VALIDATION IN 2011-2020 ($MILLION)
TABLE 33 GLOBAL DIAGNOSTIC BIOMARKER MARKET OF OTHER SERVICES IN 2011-2020 ($MILLION)
TABLE 34 GLOBAL DIAGNOSTIC BIOMARKER MARKET IN 2011-2020 ($MILLION)
TABLE 35 TYPES OF DEVELOPMENTS FROM 2013-2010
TABLE 36 RECENT DEVELOPMENT IN PRODUCT LAUNCH
TABLE 37 PRODUCT LAUNCHES FROM 2013-2010
TABLE 38 COLLABORATION AND PARTNERSHIP
TABLE 39 PARTNERSHIP AND COLLABORATION FROM 2013-2010
TABLE 40 RECENT DEVELOPMENT IN CLEARANCE AND APPROVAL
TABLE 41 DIAGNOSTIC BIOMARKER APPROVAL AND CLEARANCE FROM 2013-2010
TABLE 42 RECENT DEVELOPMENT IN MERGERS AND ACQUISITION
TABLE 43 MERGER AND ACQUISITION FROM 2013-2010
TABLE 44 ABBOTT LABORATORIES BUSINESS SNAPSHOT
TABLE 45 AGILENT TECHNOLOGIES INC. BUSINESS SNAPSHOT
TABLE 46 AUSHON BIOSYSTEM BUSINESS SNAPSHOT
TABLE 47 BIO-RAD LABORATORIES BUSINESS SNAPSHOT
TABLE 48 EISAI CO. LTD BUSINESS SNAPSHOT
TABLE 49 EPISTEM COMPANY BUSINESS SNAPSHOT
TABLE 50 GE HEALTHCARE BUSINESS SNAPSHOT
TABLE 51 ROCHE DIAGNOSTICS LIMITED BUSINESS SNAPSHOT
TABLE 52 SIEMENS INC. BUSINESS SNAPSHOT
TABLE 53 THERMO FISHER SCIENTIFIC INC. BUSINESS SNAPSHOT

 

LIST OF FIGURES:

FIG. 1 PATENTS APPLICATION FILLED BY GENERAL ELECTRICAL FOR IMAGING TECHNOLOGY IN INDIA (2012)
FIG. 2 SPIDER-CHART FOR CHANGES IN KEY ADVANTAGES FROM 2013-2020
FIG. 3 EXPECTED GROWTH OF BIOMARKERS APPLICATION FOR CANCER TESTING
FIG. 4 PATENT ANALYSIS BY GEOGRAPHY 2013
FIG. 5 TOP 10 KEY STRATEGIES SPIDER CHART 2012-2020
FIG. 6 EXPECTED GROWTH IN CAGR FROM 2011-2020 FOR DIAGNOSTIC BIOMARKER TECHNOLOGY
FIG. 7 EXPECTED GROWTH IN CAGR FROM 2011-2020 FOR DIAGNOSTIC BIOMARKERS IN APPLICATION
FIG. 8 EXPECTED GROWTH IN CAGR FROM 2011-2020 FOR DIAGNOSTIC BIOMARKERS IN SERVICES
FIG. 9 TOP 3 WINING STRATEGIES FROM 2012-2020
FIG. 10 TOP 10 COUNTRIES IN CANCER POPULATION (PER 100,000 PEOPLE) 2011
FIG. 11 CANCER STATISTICS FOR ESTIMATED NEW CASES AND DEATHS IN U.S. FOR 2012
FIG. 12 LEADING CAUSES OF MORTALITY IN U.S. 2012
FIG. 13 COST ON ALZHEIMER`S DISEASE TO U.S. IN 2013 (IN BILLION)
FIG. 14 ESTIMATED DEATHS VS. ESTIMATED CASES IN DIFFERENT TYPES OF CANCER IN NORTH AMERICA 2013
FIG. 15 DEVELOPMENTAL STRATEGIES ADOPTED FROM 2013-2010
FIG. 16 DIAGNOSTIC BIOMARKER PRODUCT LAUNCH BY COMPANIES FROM 2013-2010
FIG. 17 PARTNERSHIP AND COLLABORATION OF COMPANIES FROM 2013-2010
FIG. 18 CLEARANCE AND APPROVAL OF TOP 5 COMPANIES FROM 2013-2010
FIG. 19 MERGERS AND ACQUISITION FROM 2013-2010
FIG. 20 ABBOTT LABORATORIES, INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 21 ABBOTT LABORATORIES, INC.  FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 22 SWOT ANALYSIS OF ABBOTT LABORATORIES
FIG. 23 AGILENT TECHNOLOGIES INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 24 AGILENT TECHNOLOGIES INC. FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 25 SWOT ANALYSIS OF AGILENT TECHNOLOGIES
FIG. 26 SWOT ANALYSIS OF AUSHON BIOSYSTEM
FIG. 27 BIO-RAD LABORATORIES FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 28 BIO-RAD LABORATORIES FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 29 SWOT ANALYSIS OF BIO-RAD LABORATORIES
FIG. 30 EISAI CO. LTD FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 31 EISAI CO. LTD FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 32 SWOT ANALYSIS OF EISAI CO. LTD
FIG. 33 EPISTEM FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 34 EPISTEM FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 35 SWOT ANALYSIS OF EPISTEM
FIG. 36 GE HEALTHCARE FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 37 GE HEALTHCARE FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 38 SWOT ANALYSIS GE HEALTHCARE
FIG. 39 ROCHE DIAGNOSTICS LIMITED FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 40 ROCHE DIAGNOSTICS LIMITED FINANCIAL REVENUES (DIAGNOSTIC DIVISION) BY GEOGRAPHY (2012)
FIG. 41 SWOT ANALYSIS OF ROCHE DIAGNOSTICS LIMITED
FIG. 42 SIEMENS INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 43 SIEMENS INC. FINANCIAL REVENUES BY GEOGRAPHY (2012)
FIG. 44 SWOT ANALYSIS OF SIEMENS
FIG. 45 THERMO FISHER SCIENTIFIC INC. FINANCIAL REVENUES BY BUSINESS UNITS (2012)
FIG. 46 THERMO FISHER SCIENTIFIC INC. FINANCIAL REVENUES BY GEOGRAPHIC AREAS (2012)
FIG. 47 SWOT ANALYSIS OF THERMO FISHER SCIENTIFIC INC.

SIMILAR MARKET STUDIES

Published Reports

Regenerative medicines have the unique ability to repair, replace and regenerate tissues and organs, affected due to some injury, disease or due to natural aging process. These medicines are capable of restoring the functionality of cells and tissues. These medicines find applicability in wide range of degenerative disorders including dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications. Researchers are engaged in developing technologies based on biologics, genes, somatic as well as stem cells.
30 Jun 2014 | Price: $4515(SU) | View Details >>

Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. Its a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period.
27 May 2014 | Price: $4515(SU) | View Details >>

The bioinformatics market is expected to grow to $12.86 billion by 2020 with a CAGR of 21.2% during 2014-2020. Bioinformatics is an interdisciplinary field that is used in the development and storage of data, thus helping in the analysis, organization and retrieval of the biological data. Bioinformatics has various applications and thus forms part of almost all the fields in biology. Bioinformatics form a part of agriculture, animal breeding, molecular medicine, preventive medicine, etc. The major factors driving the bioinformatics market is the need for integrated data, rising demand for drug development and discovery, the increasing focus in genomics & proteomics and the favorable government initiatives.
28 May 2014 | Price: $4515(SU) | View Details >>

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market.
10 Jun 2014 | Price: $4515(SU) | View Details >>

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies.
21 Jan 2014 | Price: $4515(SU) | View Details >>

Upcoming Reports

STDs are sexually transmitted infections generally known as sexually transmitted diseases (STD) or venereal diseases. These are illness transmitted between humans as a result of sexual behavior. A variety of methods have been employed for the identification and assessment of these diseases based on their types. Some of the commonly known types of STDs are Gonorrhea, Syphilis and HIV AIDS. The objective of this report is to provide an in-depth understanding of the market scenario of diagnostic testing of STDs.
Price: $4515 | Pre Book Price: $4515 | View Details >>

Tissue engineering is the combination of biology medicine and engineering to create products that would improve or replace biological functions or organs. More than a decade ago, the industry introduced the first FDA approved tissue-engineering product, which was a skin substitute product. These products provide natural regeneration of tissues or cells, and hence are highly effective. The medical biotechnology industry was estimated to be $160 billion in 2012.The major drivers in this industry are chronic wound and orthopedic application segment.
Price: $4515 | Pre Book Price: $4515 | View Details >>

Cardiac Biomarkers are protein substances released into the blood stream from damaged heart muscles. These are the biological parameters that are used to detect the presence of cardiovascular diseases. According to World Health Organization, in 2008, 17.3 million people died due to cardiovascular diseases and it is expected to reach 23.3 million by 2030. This increase in cardiovascular diseases across the globe widens the global cardiac biomarkers market. With the prevalence of these cardiovascular diseases, demand for cardiac biomarkers would increase in future for early diagnosis and disease management.
Price: $4515 | Pre Book Price: $4515 | View Details >>

The endocrine system comprises of the endocrine glands such as the pituitary, thyroid, pancreas, adrenal, etc. These glands secrete hormones that regulate the bodys metabolism, growth, sexual development and function. Endocrine tests help in assessing the normal functioning of the endocrine gland by checking the hormone levels. The tests detect the imbalance in hormonal levels. The various tests, their advantages and uses are described in the report. The endocrine testing market is driven by the increasing incidences of endocrine disorders such as diabetes, thyroid disorders, infertility, etc.
Price: $4515 | Pre Book Price: $4515 | View Details >>

C-Reactive Protein Tests are blood tests that measure the levels of C-Reactive Protein. C-reactive protein is a protein that is produced by the liver and its level increase when there is inflammation in the body. C-reactive tests identify and keep track of infections and diseases that cause inflammation such as certain types of cancers, cardiovascular diseases, arthritis, etc. According to the WHO, an estimated 17.3 million people died of cardiovascular diseases in 2008 alone. C-reactive protein tests estimate the risks of a person suffering from heart attacks or strokes. The main drivers for this market are the increasing incidences of cardiovascular diseases, and the sheer volume of tests required. Lack of public awareness would be a challenge to growth of this market.
Price: $4515 | Pre Book Price: $4515 | View Details >>
NEED MORE INFORMATION?
Call
+1 617 674 413
PURCHASE OPTIONS

Single User
By obtaining a Single User License, you and your organization concur that only an individual uses this report either electronically or online. The right to use or stockpiling of the report should be confined only to one authorized computer. User will have authorization to print one duplicate of the report for individual use, yet may not be replicated for circulation. Additional copies for this report may also be order at discounted price for use by addition readers/users.
$4515

Multi User 
Multi-User license permits you to access the report from eight authorized computers. It does not permit you to display it on your company website and permits you to only print 5 copies of the report that shall not be reproduced for circulation.
$7515

Corporate  
With corporate use license, the complete or part of the content of the report can be shared or made available to other persons, other divisions and subsidiaries of same company. However, reproduction or redistribution of the report in is prohibited without the prior permission of Allied Market Research. The publisher will, in turn, regard the privacy of the purchaser and will keep it confidential. Upon buying single or multi-user license, buyer must provide the names and email ids of the authorized users of this report.
$10515


WHY ALLIED MARKET RESEARCH?
INFALLIBLE METHODOLOGY
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader